Are you R M Chichmanian?

Claim your profile

Publications (109)178.56 Total impact

  • British Journal of Haematology 03/2008; 81(3):459 - 460. · 4.94 Impact Factor
  • C Izambart, F Rocher, C Zur, R M Chichmanian, P Gastaud
    [Show abstract] [Hide abstract]
    ABSTRACT: Topiramate, an antiepileptic medication, has been widely used since its recent indication for migraine prophylaxis. We report a case of bilateral angle-closure glaucoma and acute myopia in a 44-year-old woman on oral topiramate therapy initiation for migraine prophylaxis. Intraocular pressure was 31 mmHg right and 32 mmHg left, myopia was 4 diopters. Topiramate was interrupted and general and local hypotensive treatment begun and rapidly stopped after improvement. Iridotomy was also performed. Fifteen days later, complete resolution was observed on ophthalmologic examination: anterior chambers were deep, myopia fully regressed, intraocular pressure returned to normal, and the visual field was complete. This new case prompts discussion on current reports in the literature and French drug monitoring database cases in this context.
    Journal francais d'ophtalmologie 06/2007; 30(5):e11. · 0.51 Impact Factor
  • C. Izambart, F. Rocher, C. Zur, R. M. Chichmanian, P. Gastaud
    [Show abstract] [Hide abstract]
    ABSTRACT: Topiramate, an antiepileptic medication, has been widely used since its recent indication for migraine prophylaxis. We report a case of bilateral angle-closure glaucoma and acute myopia in a 44-year-old woman on oral topiramate therapy initiation for migraine prophylaxis. Intraocular pressure was 31 mmHg right and 32 mmHg left, myopia was 4 diopters. Topiramate was interrupted and general and local hypotensive treatment begun and rapidly stopped after improvement. Iridotomy was also performed. Fifteen days later, complete resolution was observed on ophthalmologic examination: anterior chambers were deep, myopia fully regressed, intraocular pressure returned to normal, and the visual field was complete. This new case prompts discussion on current reports in the literature and French drug monitoring database cases in this context.
    Journal Francais D Ophtalmologie - J FR OPHTALMOL. 01/2007; 30(5).
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionRituximab is indicated for the treatment of low-grade lymphoma. Pulmonary toxicity related to rituximab is exceptional.Case reportHere we report a patient with non-Hodgkin lymphoma treated with “CHOP“ chemotherapy (cyclophosphosphamide, adriamycin, vincristine and prednisolone) and rituximab who developed an interstitial pneumonia with acute respiratory failure. The differential diagnosis of this clinical and radiological diagnosis is discussed.ConclusionAlthough cases of interstitial pneumonia associated with rituximab are rare, they may be severe and thus any patient experiencing respiratory symptoms on this therapy should be monitored closely.
    Revue des Maladies Respiratoires. 01/2004;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In HIV-infected patients, ritonavir, a potent cytochrome P450 inhibitor, is increasingly used to improve the pharmacokinetic profile of the associated protease inhibitor. HIV physicians are often faced with potential drug-drug interaction while treating associated diseases. We report the case of an HIV-infected patient with clinical features of Cushing's syndrome due to the interaction of low dose ritonavir with inhaled fluticasone propionate (FP). Safety of life-long CYP450 inhibition has still to be demonstrated.
    Journal of Infection 05/2002; 44(3):194-5. · 4.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Monoclonal TNF alpha antibodies are a new treatment of severe rheumatoid arthritis. One of the possible side effects is the appearance of opportunistic infections. We report here on three cases of disseminated tuberculosis observed in patients undergoing treatment with infliximab. A 45-year-old woman, treated with infliximab, was hospitalised after five infusions for fever and dyspnoea. The exams showed pulmonary and peritoneal tuberculosis. The second case is a 75-year-old woman whose symptoms were fever, cough and cervical adenopathy after three infliximab infusions. Diagnosis was disseminated tuberculosis. The third case is a 59-year-old man who was hospitalised for an infectious syndrome with dyspnoea, after two infliximab infusions. We discovered pulmonary tuberculosis. These three cases added to the 68 cases of tuberculosis registered with the treatment of infliximab. This confirms the risk of severe opportunist infectious side effects. TNF alpha is a cytokine which has anti-infectious properties. These tuberculoses are severe and generalized. It is recommended to search for an active or latent tuberculosis before beginning treatment with infliximab, and to check these patients frequently.
    La Revue de Médecine Interne 04/2002; 23(3):312-6. · 0.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. – Monoclonal TNFα antibodies are a new treatment of severe rheumatoid arthritis. One of the possible side effects is the appearance of opportunistic infections. We report here on three cases of disseminated tuberculosis observed in patients undergoing treatment with infliximab.Exegesis. – A 45-year-old woman, treated with infliximab, was hospitalised after five infusions for fever and dyspnoea. The exams showed pulmonary and peritoneal tuberculosis. The second case is a 75-year-old woman whose symptoms were fever, cough and cervical adenopathy after three infliximab infusions. Diagnosis was disseminated tuberculosis. The third case is a 59-year-old man who was hospitalised for an infectious syndrome with dyspnoea, after two infliximab infusions. We discovered pulmonary tuberculosis.Conclusion. – These three cases added to the 68 cases of tuberculosis registered with the treatment of infliximab. This confirms the risk of severe opportunist infectious side effects. TNFα is a cytokine which has anti-infectious properties. These tuberculoses are severe and generalized. It is recommended to search for an active or latent tuberculosis before beginning treatment with infliximab, and to check these patients frequently.
    Revue De Medecine Interne - REV MED INTERNE. 01/2002; 23(3):312-316.
  • La Revue de Médecine Interne 01/2002; 23(3). · 0.90 Impact Factor
  • Source
    V Bourg, C Lebrun, R M Chichmanian, P Thomas, M Frenay
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of haematologic toxicity of valproate (VPA) ranges from 1% to 32% and consists mainly of asymptomatic, dose-dependent thrombopenia. We describe a potentiation of haematologic side-effects of nitroso-urea (NU) when prescribed in association with VPA. We followed a cohort of 70 patients (58 men, 22 women, mean age: 56 years, range 20-75 years). Patients with high-grade gliomas were treated with up-front chemotherapy regimen consisting of fotemustine (d3: 100 mg/m2), cisplatin (d1-3: 33 mg/m2) and etoposide (d1-3: 75 mg/m2) followed by whole brain radiotherapy at progression. Sixty patients required anti-epileptic drugs (AED) for either a single, well-documented epileptic seizure, or immediatly initiated after neurosurgical procedures. AED included VPA (35 of 60), phenobarbital (PB) (17 of 60), carbamazepine (CBZ) (2 of 60) and phenytoin (PHT) (3 of 60). Two patients had both PB and CBZ and one PB and PHT. Haematologic toxicity (grade 3-4 thrombopenia, neutropenia or both) was observed in 37 of 70 (52.85%) patients. Among them 24 (65%) had VPA. Group C were patients treated with fotemustine alone with or without VPA (23 patients). When prescribed in association with a fotemustine-cisplatin regimen, VPA treatment results in a three-fold higher incidence of reversible thrombopenia, neutropenia or both. Haematologic side-effects decrease after AED modification during the continued chemotherapy. This adverse event should be managed with caution.
    Annals of Oncology 03/2001; 12(2):217-9. · 7.38 Impact Factor
  • Revue De Medecine Interne - REV MED INTERNE. 01/2001; 22:82-82.
  • A Spreux, B Baldin, R M Chichmanian
    [Show abstract] [Hide abstract]
    ABSTRACT: Directed by the French Agency for the Safety of Health Products (AFSSAPS), the French pharmacovigilance system is in charge of the surveillance of drugs after they have been provided by AFSSAPS with official marketing authorizations that are in France either 'new drug approval certificates' (AMM) or 'temporary utilization authorizations' (ATU). About 3,700 pharmaceutical products are concerned which are used either for treatment (all drugs and remedies, inclusive plasma-derived blood products), prevention (vaccines, oral contraception), diagnosis (contrast products, ...), or to modify a physiologic function (general or local anesthetics). At the national level, the main actors of the system are AFSSAPS and its National Commission, the 31 Regional Centers of Pharmacovigilance, all the health professionnals, and the pharmaceutical laboratories. Health professionnals are held to notify any suspected serious or unexpected adverse effects as quickly as possible. The analysis of data collected by the national report bank permits alerts and inquiries about drug safety. Furthermore regional centers of pharmacovigilance are responsible for drug information. The French pharmacovigilance system works in cooperation with the European Agency for the Evaluation of Medicinal Products.
    Transfusion Clinique et Biologique 08/1999; 6(4):254-9. · 0.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leishmaniasis in a patient with Wegenerís disease raises the problem of amphotericin toxicity further compromising the pre-existing renal disorder. An anemic patient treated for Wegenerís disease developed visceral leishmaniasis. This renal failure patient was treated with lipid complex amphotericin B and liposomal amphotericin B. We report outcome at 10 months follow-up. The new formulations of amphotericin B allow effective treatment of visceral leishmaniasis in renal failure patients. Long-lasting results are probably favored by the interruption of immuno-suppressive therapy.
    La Presse Médicale 06/1999; 28(18):959-61. · 0.87 Impact Factor
  • E Rosenthal, F Sala, R M Chichmanian, M Batt, J P Cassuto
    JAMA The Journal of the American Medical Association 04/1999; 281(11):987. · 29.98 Impact Factor
  • Gastroentérologie Clinique et Biologique 02/1999; 23(1):152-3. · 1.14 Impact Factor
  • E. Rosenthal, F. Sala, R. M. Chichmanian, M. Batt, J. P. Cassuto
    Revue De Medecine Interne - REV MED INTERNE. 01/1999; 20.
  • A. Spreux, B. Baldin, R. M. Chichmanian
    [Show abstract] [Hide abstract]
    ABSTRACT: Directed by the French Agency for the Safety of Health Products (AFSSAPS), the French pharmacovigilance system is in charge of the surveillance of drugs after they have been provided by AFSSAPS with official marketing authorizations that are in France either ‘new drug approval certificates’ (AMM) or ‘temporary utilization authorizations’ (ATU). About 3,700 pharmaceutical products are concerned which are used either for treatment (all drugs and remedies, inclusive plasma-derived blood products), prevention (vaccines, oral contraception), diagnosis (contrast products,…),or to modify a physiologic function (general or local anesthetics). At the national level, the main actors of the system are AFSSAPS and its National Commission, the 31 Regional Centers of Pharmacovigilance, all the health professionnals, and the pharmaceutical laboratories. Health professionnals are held to notify any suspected serious or unexpected adverse effects as quickly as possible. The analysis of data collected by the national report bank permits alerts and inquiries about drug safety. Furthermore regional centers of pharmacovigilance are responsible for drug information. The French pharmacovigilance system works in cooperation with the European Agency for the Evaluation of Medicinal Products.
    Transfusion Clinique Et Biologique - TRANSFUS CLIN BIOLOGIQUE. 01/1999; 6(4):254-259.
  • [Show abstract] [Hide abstract]
    ABSTRACT: An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone. Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia. These responded to systemic steroids and immunoglobulins. Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.
    The American Journal of Gastroenterology 06/1998; 93(5):836-7. · 9.21 Impact Factor
  • Gastroentérologie Clinique et Biologique 02/1998; 22(1):106-7. · 1.14 Impact Factor
  • Source
    P Hastier, F Longo, M Buckley, R M Chichmanian, J P Delmont
    [Show abstract] [Hide abstract]
    ABSTRACT: A woman who developed acute pancreatitis following ingestion of low dose codeine, with positive rechallenge, is described. As this is the first case report of pancreatitis being induced solely by codeine, this side effect must be rare in view of the widespread consumption of this drug.
    Gut 12/1997; 41(5):705-6. · 10.73 Impact Factor
  • F Peyrade, B Taillan, R M Chichmanian, C Lebrun, P Dujardin
    La Presse Médicale 11/1997; 26(31):1489. · 0.87 Impact Factor